Swedish Orphan Biovitrum AB
SOBI.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$148.78B
Close$
$368.94
13.9% downside
Current Fair Value
13.9% downsideOvervalued by 13.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $148.78 Billion |
|---|---|
| Enterprise Value | $165.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.39 |
| Beta | 0.27 |
| Outstanding Shares | 346,180,000 |
Return
| Return on Equity | 3.27% |
|---|---|
| Return on Assets | 1.67% |
| Return on Invested Capital | 4.65% |
Valuation & Multiples
| P/E Ratio | 107.91 |
|---|---|
| PEG | 148.87 |
| Price to Sales | 4.87 |
| Price to Book Ratio | 3.51 |
| Enterprise Value to Revenue | 5.4 |
| Enterprise Value to EBIT | 56.45 |
| Enterprise Value to Net Income | 119 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 16, 2026
EPS Estimate
$3.36
Average shareholder expectationRevenue Estimate
$7.33 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$6.07
Average shareholder expectationRevenue Estimate
$8.98 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Swedish Orphan Biovitrum AB (publ)
1,888 employees
CEO: Guido Oelkers Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic ...